Tris Pharma Launches Phase 3 Trials for Cebranopadol, Aiming for Safer Pain Relief with Lower Addiction Risk

The safety and effectiveness of cebranopadol, a dual-NMR agonist for the treatment of moderate-to-severe acute pain, are being investigated in Phase 3 studies by Tris Pharma, a biopharmaceutical firm that specialises in treating neurological diseases, pain, ADHD, and addiction. More than 500 patients will be enrolled in the studies at clinical trial sites around the United States, and the findings will be included in the New Drug Application (NDA) submitted to the FDA in order to have cebranopadol approved.

With a reduced risk of major side effects, dependence, and potential addiction, cebranopadol is intended to take advantage of the body's natural pain-modulating mechanisms. By combining the analgesic benefits of the MOP receptor with the safety and analgesic qualities of the NOP receptor, it may be possible to provide pain relief comparable to that of opioids. To far, approximately 2,000 patients have participated in over 30 effectiveness and safety clinical studies that have thoroughly characterised the experimental treatment. Based on the data from these trials, cebranopadol appears to be a useful medication for treating both acute and chronic pain, including neuropathic pain. It also appears to reduce many of the negative side effects associated with opioids and may greatly reduce the risk of addiction and overdose.

To sum up, the start of these Phase 3 trials is an important step towards giving patients access to a very safe and effective pain management treatment.